Comparison of Emergence/Dysphoric Reaction Frequency of Using 2 Different Doses Ketamine

NCT ID: NCT05786365

Last Updated: 2024-07-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

108 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-01-01

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to compare the effect of using different doses of ketamine on producing dysphoric reaction.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Our study is a randomized single-blind observational study. In our study, the effect of producing a dysphoric reaction will be observed by administering ketamine at doses of 0.5 mg/kg and 1 mg/kg to two randomly randomized different groups who presented to our hospital and needed interventional sedation analgesia. For this reason, our patients with an indication for interventional sedation and analgesia will be taken to the observation room and their vital values will be monitored. Two different vascular accesses with at least 18 gauge will be obtained from the two extremities. The patients will be randomized and 0.5 mg/kg IV ketamine will be given to the 1st group. The second group will be given 1 mg/kg IV ketamine. Then, the patients will be recorded in terms of blood pressure, pulse and saturation at the 5th minute, 15th minute and 30th minute. We will give iv ketamine to two different patient groups as 0.5 mg per kilogram in the 1st group and 1 mg per kilogram in the 2nd group and we will observe the patients.We scored the patients between +4 and -5 points on the RASS scale. Patients who were sedated to an extent that they could not be awakened were scored as -5, patients who were dangerously agitated +4, and patients who were awake were scored 0. We considered patients who scored +2 on the Richmond agitation sedation scale as having developed a dysphoric reaction.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sedation Complication

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

The group given 0.5 mg/kg ketamine

In this group we will give 0.5 mg/kg ketamine and we observe for disphoric reaction

Ketalar 50 MG/ML Injectable Solution

Intervention Type DRUG

Ketamine will be administered to two different groups as 0.5 mg/kg and 1 mg/kg

The group given 1 mg/kg ketamine

In this group we will give 1 mg/kg ketamine and we observe for disphoric reaction

Ketalar 50 MG/ML Injectable Solution

Intervention Type DRUG

Ketamine will be administered to two different groups as 0.5 mg/kg and 1 mg/kg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ketalar 50 MG/ML Injectable Solution

Ketamine will be administered to two different groups as 0.5 mg/kg and 1 mg/kg

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ketamine hydrochloride

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Glaskow coma scale should be 15
* Inability to speak, read or understand English or Turkish
* Patients needing procedural sedation and analgesia

Exclusion Criteria

* Patients with active coronary artery disease
* Patients with liver or kidney transplant
* Patients with conditions that change consciousness such as substance intake, alcohol intake
* Patients with advanced COPD or Heart failure
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Aksaray University Training and Research Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

çağrı türkücü

cagriturkucu

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kamil Kokulu, M.D.

Role: PRINCIPAL_INVESTIGATOR

Aksaray UTRH

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Çağrı Türkücü

Aksaray, , Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

cagriturkucu

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Ketamine Versus Propofol as ICU Sedation
NCT06243822 COMPLETED PHASE4
Sevoflurane Induced Emergence Agitation
NCT02022488 COMPLETED PHASE4
Ketamine and Propofol for Upper Endoscopy
NCT02295553 COMPLETED PHASE4
Emergence Agitation of Sevoflurane in Pediatric
NCT06830564 COMPLETED PHASE2/PHASE3
Sevoflurane in Electroconvulsive Therapy
NCT01905904 COMPLETED PHASE4
Safety of Remifentanil Infusion
NCT01303627 COMPLETED PHASE4